|Bid||1.30 x 1500|
|Ask||1.60 x 700|
|Day's Range||1.24 - 1.55|
|52 Week Range||0.83 - 4.75|
|PE Ratio (TTM)||0.26|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||19.00|
NEW YORK, Aug. 15, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to the fostering of technology, today announced the addition of Dr. Scott T. Tagawa to the Company's Technology Advisory Board. The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena. Dr. Scott T. Tagawa, MD, MS is the Richard A. Stratton Associate Professor in Hematology and Oncology and an Associate Professor of Clinical Medicine and of Clinical Urology at Weill Cornell Medicine.
NEW YORK, Aug. 2, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to fostering of technology, today issued a letter to shareholders. It is with great pleasure that I take this opportunity to update you on recent events at the Company and describe in greater detail our strategic path forward. The fundamentals at Spherix are stronger than they have been in recent memory and our path to value creation is moving forward with precision and focus.
NEW YORK, July 27, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to fostering of technology, today announced that Anthony Hayes, CEO of Spherix Inc., joins the board of directors at Hoth Therapeutics Inc.